Abstract 14P
Background
Homologous recombination deficiency (HRD) is a clinically-proven indicator of sensitivity against platinum-based chemotherapy and PARP inhibitors in various malignancies, including ovarian cancers. Until now, HRD prediction has been carried out by detecting the deleterious mutations of the BRCA1 or BRCA2 gene or measuring genomic scar, i.e., scarHRD. However, the scarHRD method has limitations in applying tumors without matched germline data. Investigating HRD-specific transcriptomic signatures is one of the tangible approaches to predicting HRD in tumor-only samples. Although several RNA-seq-based HRD prediction algorithms have been developed, they support mainly cohort-wise classification regarding HRD status yet do not provide an equivalent value to scarHRD. The transformation into scarHRD from transcriptomic data would be highly valuable for clinical application and research use.
Methods
Here, we developed an algorithm of transcriptome-based HRD analysis, i.e., expHRD. The prediction model was established using the elastic net in TCGA-pan cancer training set. HRD geneset for applying expHRD calculation using single-sample geneset enrichment analysis was derived by bootstrap technique.
Results
expHRD is a clinically applicable RNA-seq-based HRD prediction platform in tumor-only samples. In clinic, expHRD can provide supportive information for predicting platinum or PARP inhibitor responses by providing predicted scarHRD score. We could extract the expHRD to analyze the inter-cohort evaluation, HRD-associated gene expression profile, mutations, or tumor types in samples without matched germline data, such as cryopreserved or formalin-fixed tissues, cell lines, or organoids.
Conclusions
Developing a targeted transcriptomic panel for calculating expHRD would be a cost-effective approach to linking our platform with the clinic.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract